^
Association details:
| Biomarker: | STRN-ALK fusion + EML4-ALK fusion + EGFR T790M |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) + Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Coexistence of a secondary STRN–ALK, EML4–ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation
Published date:
07/04/2021
Excerpt:
...NGS test revealed EGFR exon20 T790M and the appearance of a novel double-fusion EML4–ALK and STRN–ALK. A combined therapeutic regimen of crizotinib plus osimertinib showed a promising prognosis confirmed with lung CT scans showing stable lesions without any new metastasis.
DOI:
10.1097/CAD.0000000000001094
